Drug Profile
Granisetron controlled-release - Heron Therapeutics
Alternative Names: APF-530; SustolLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator A.P. Pharma
- Developer Heron Therapeutics
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting
Most Recent Events
- 30 Sep 2020 Heron Therapeutics withdraws phase II trial for Chemotherapy-induced nausea and vomiting (In adults, Prevention) prior to enrolment in USA (SC, Extended release) in September 2020 (NCT04085393)
- 31 Oct 2016 Launched for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in USA (SC) (First global launch) before October 2016
- 10 Aug 2016 Registered for Chemotherapy induced nausea and vomiting (Prevention, Combination therapy) in USA (SC) (First global approval)